Analyses of Exosomes in the Cerebrospinal Fluid for Breast Cancer Patients With Suspicion of Leptomeningeal Metastasis.

Last updated: September 23, 2025
Sponsor: Centre Oscar Lambret
Overall Status: Trial Not Available

Phase

N/A

Condition

Neoplasm Metastasis

Breast Cancer

Cancer

Treatment

Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are "confirmed", "probable" or "possible", leading to leptomeningeal metastase specific treatment

Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are "Lack of evidence" according to EANO-ESMO classification

Cerebrospinal fluid and blood sample collection at the initial diagnostic assessment

Clinical Study ID

NCT03974204
Exo-LCR
2018-A02358-47
  • Ages > 18
  • Female

Study Summary

This is a multicenter, interventional, prospective study among breast cancer patients with a suspicion of metastatic meningitis. The current study aims to assess the use of proteomic profile issued from cerebrospinal fluid microvesicles for diagnosis of leptomeningeal metastases.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Patient with histologically proven breast cancer

  • Patient with suspected metastatic leptomeningitis

  • Age ≥ 18 years

  • Patient covered by the French social security regime

  • Signed written informed consent

Exclusion

Exclusion Criteria:

  • History of cancer other than the one being treated

  • Contraindication to carrying out the lumbar puncture or cerebrospinal MRI

  • Pregnant or breastfeeding patient

Study Design

Treatment Group(s): 3
Primary Treatment: Cerebrospinal fluid and blood sample collection if conclusions of initial diagnostic assessment are "confirmed", "probable" or "possible", leading to leptomeningeal metastase specific treatment
Phase:
Study Start date:
July 01, 2019
Estimated Completion Date:
October 31, 2023

Study Description

The aim of this study is to describe the association between the initial proteomic profile issued from cerebrospinal fluid microvesicles and the initial cytological analysis of the cerebrospinal fluid in breast cancer patients with a suspicion of metastatic meningitis.

Other objectives of the study include:

  • Describing the association between the initial proteomic profile and:

    • the histological types and hormonal receptors status of the breast cancer,

    • the likelihood of leptomeningeal metastasis according to the EANO-ESMO classification (Lack of evidence / possible / probable / confirmed) ,

    • the likelihood of leptomeningeal metastasis according to the EANO-ESMO classification, combined with histological type and hormonal receptors status.

  • Evaluate the prognostic value of the proteomic profiling for overall survival, according to the EANO-ESMO classification and other known prognosis factors, in patients classified "possible", "probable" or "confirmed" leading to leptomeningeal metastases specific treatment,

  • Evaluate the impact of the evolution of the proteomic profile a month after the start of this treatment on the overall survival, in patients with leptomeningeal metastases specific treatment,

  • Evaluate the association between the proteomic profile and the EANO-ESMO classification at least 3 months after the initial EANO-ESMO classification,

  • Evaluate the evolution of the proteomic profile 3 months after the initial EANO-ESMO classification, in patients initially classified "lack of evidence", broadly and according to the evolution of cytology, the administered treatments and to the EANO-ESMO response if applicable,

  • Compare the proteomic profiles issued from cerebrospinal fluid and blood

Connect with a study center

  • Centre Oscar Lambret

    Lille, Hauts-de- France 59020
    France

    Site Not Available

  • Centre Hospitalier Régional Universitaire de Lille

    Lille, Hauts-de-France 59000
    France

    Site Not Available

  • Centre Hospitalier Régional Universitaire de Lille

    Lille 2998324, Hauts-de-France 11071624 59000
    France

    Site Not Available

  • Centre Oscar Lambret

    Lille 2998324, Hauts-de-France 11071624 59020
    France

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.